Intravesical bacillus Calmette-Guérin (BCG) with and without isoniazid (INH) is associated with outcomes superior to those intravesical epirubicin in patients with intermediate- and high-risk Ta and ...
Use of 2 sequential induction courses of BCG for high-risk NMIBC rather than standard induction with maintenance therapy showed an excellent response rate. A novel strategy for using bacillus Calmette ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Intravesical bacillus Calmette-Guérin (BCG) therapy reduces recurrence in non-muscle invasive bladder cancer (NMIBC). Various scoring models have been developed to predict recurrence, and this study ...
SAN ANTONIO -- More than 70% of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) achieved complete responses to a novel gene therapy, a small preliminary trial showed. Across ...
Aidixi combined with BCG showed 100% clinical complete response rates at three and six months in high-risk NMIBC patients with HER2 expression. Event-free survival at six months was 100% for patients ...
Credit: ImmunityBio. Nogapendekin alfa inbackicept-pmin is an interleukin-15 receptor agonist. The Food and Drug Administration (FDA) has approved Anktiva ® (nogapendekin alfa inbakicept-pmln) with ...
A treatment combination of Anktiva and Bacillus Calmette-Guérin was approved by the FDA for certain patients with non-muscle-invasive bladder cancer. The Food and Drug Administration (FDA) has ...
Bladder cancer is one of the more common cancers worldwide. It is considered a major health care problem with a high financial burden. Of these cases, 75% are non-muscle-invasive, which characterizes ...
On Thursday, HC Wainwright initiated coverage on Relmada Therapeutics Inc. RLMD with a primary focus on bladder cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results